Given the ability of p5RHH to deliver siRNAs to tumor cells in vitro and to arthritic joints in vivo, as well as the similarities between arthritic joints and the tumor environment, we hypothesized that p5RHH could be used to deliver AXL-targeting siRNAs to high-grade ovarian and uterine serous tumor for potential clinical translation. Here, AXL is linked to neoplasm.